MSD Korea’s antibody, Zerbaxa’s approval in Korea
‘Zerbaxa(generic name: ceftolozane+tazobactam),’ a MSD Korea’s(CEO Avi BenShoshan) new antibody, acquired sales approval in Korea. On the 7th, the Ministry of Food and Drug Safety(MFDS) approved the Zerbaxa’s commercialization as a combination therapy with metronidazole for the treatment of compl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
